PRKCD and inflammatory bowel disease: Our study reported that cinacalcet inhibited production of the inflammatory cytokines TNFα, IL-1β, and IL-6, via suppression of the PKCδ/ERK/P65 signaling pathway, by targeting NK1R, indicating that cinacalcet might be repurposed for use in treating IBD.